Asymmetric Catalysis Patents: Who Leads, Where the Gaps Are 2026
- 47.5% of all 335 records sit with just five assignees, and the leader alone accounts for 93 records — this field is claim-dense at the top, not evenly spread.
- Filing peaked in 2020 at 15 and has since flattened, with the 2022 midpoint at only 5 — momentum has cooled well before the most recent, still-partial year.
- B01J catalysis claims cover 75.5% of records while fermentation-based routes (C12P) sit at just 2.4% — enzymatic and biocatalytic asymmetric synthesis is comparatively open.
What this landscape covers
This dataset tracks 335 published records at the intersection of asymmetric catalysis, chiral synthesis and enantioselective hydrogenation, filtered to claims touching chiral ligand design, enantiomeric excess, catalyst loading and turnover, metal removal from API, and chiral resolution alternatives. The scope is anchored to B01J31, C07B53 and C07C29, which keeps the set focused on catalytic and organic-chemistry routes rather than downstream formulation or biological use.
Coverage runs from 2015 through the 2026-07-31 cut-off. Because publication typically lags filing by around eighteen months, the most recent one to two years in any trend below will understate actual filing activity until later data catches up.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 335 records: how filing activity has moved year over year, and how those records distribute across IPC subclasses.
A peak in 2020, then a flat tail
Filing rose from zero in 2017 to a peak of 15 records in 2020, then eased back — the 2022 midpoint sits at just 5. That pattern reads as a field that had a defined burst of activity rather than one still accelerating, though the final one to two years are undercounted due to publication lag.
Catalysis and organometallic classes dominate
B01J (75.5%), C07F (71.6%) and C07C (71.3%) of the 335 records carry the bulk of claim activity, with C07B and C07D each still present in roughly half of records. A61K, C08F and C12P each sit under 4%, marking medicinal-preparation crossover, polymer-adjacent chemistry and fermentation-based synthesis as comparatively thin claim territory within this scope.
Shares are the percentage of the 335 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Asymmetric Catalysis and Chiral Synthesis with Eureka
This page is one run against one query. Ask Eureka your own question about asymmetric catalysis and chiral synthesis and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this scope
Chiral synthesis of fused bicyclic RAF inhibitors
The disclosure covers improved synthesis of fused bicyclic Raf inhibitor enantiomers at high enantiomeric excess, along with methods of using those compounds to treat diseases including cancer and colorectal cancer.US20220041595A1 — Jazz Pharmaceuticals Ireland Limited, filed 2022-02-10.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2004085378A1 | Process for the preparation of chiral beta amino acid derivatives by asymmetric hydrogenation | 200 |
| 2 | WO2002040491A1 | Ortho substituted chiral phosphines and phosphinites and their use in asymmetric catayltic reactions | 59 |
| 3 | US20050228190A1 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin | 54 |
| 4 | US5008457A | Chiral phospholane transition metal catalysts | 50 |
| 5 | US7468459B2 | Process for the preparation of chiral beta amino acid derivatives by asymmetric hydrogenation | 49 |
| 6 | WO2015149068A1 | Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis | 42 |
| 7 | WO2001021625A1 | Chiral phosphines, transition metal complexes thereof and uses thereof in asymmetric reactions | 39 |
| 8 | US6521769B1 | Chiral phosphines, transition metal complexes thereof and uses thereof in asymmetric reactions | 36 |
| 9 | WO2002026750A2 | Phosphino-aminophosphines, catalyst complexes and enantioselective hydrogenation | 34 |
| 10 | WO1991017998A1 | Chiral phospholane transition metal catalysts | 31 |
Citation counts favour older filings that have had more time to accumulate references — read them as a signal of influence within this corpus, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data says about this field
Reading the concentration, citation and receiving-office figures together points to a field with an established core and a thinner, more open periphery.
Leadership is settled, not contested
The top 5 assignees combined hold 159 of 335 records (47.5%), and the single leader accounts for 93 records on its own. That gap between first place and fifth place (15) suggests one organisation built a substantial position early and the rest of the field filed in its shadow.
Filing activity has cooled since 2020
After rising from zero in 2017 to a peak of 15 records in 2020, filing eased to 5 by the 2022 midpoint. None of the tracked assignees show positive year-on-year momentum in the latest year, which points to a technology base that has matured rather than one still in a land-grab phase.
US filing leads, but PCT and EPO both matter
The United States receives the largest single share of filings at 91, with Europe (EPO) at 47 and WIPO/PCT at 44 close behind. Australia (30), Canada (29) and Israel (21) each carry a meaningful but smaller share, indicating filers are protecting this chemistry across a fairly standard multi-jurisdiction spread rather than concentrating narrowly.
Influence concentrates in a small set of early filings
The most-cited record in this scope, on chiral beta amino acid derivatives via asymmetric hydrogenation, carries 200 citations — more than three times the next entry on the list. Because citation counts accumulate over time, this pattern reflects age and foundational status as much as ongoing relevance.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to asymmetric catalysis and chiral synthesis, with the prior art for and against each one.
Who holds the claim space, and where it thins out
The ranking covers 100 companies counted by record share, with sharp concentration at the very top and a long tail of single- or few-filing entrants below it.
One organisation dominates the top of the ranking
The leading assignee holds 93 of the 335 records in scope — well over three times the fifth-place figure of 15. Its strongest co-assignee pairing appears seven times, pointing to a long-running collaboration with a named individual inventor rather than a diffuse internal program.
The drop-off after the top 10 is steep
Tenth place sits at 8 records, and the top 10 combined hold 214 records (63.9% of the 335 in scope). Below that line, filing activity spreads thinly across the remaining ranked companies, many likely holding only a handful of records each.
No leading assignee is currently accelerating
Every assignee tracked for recent-year momentum, including the field leader, shows zero filings in the latest year, and one shows a -100% year-on-year change. Given the roughly 18-month publication lag, some of this is an artefact of timing rather than a genuine stop in R&D, but it confirms none of the leaders are visibly ramping filings right now.
| Assignee | Recent year | YoY |
|---|---|---|
| The Penn State Research Foundation | 0 | — |
| Bayer AG | 0 | -100% |
| E.I. du Pont de Nemours & Co. | 0 | — |
| Warner-Lambert Company LLC | 0 | — |
| Chirotech Technology Limited | 0 | — |
| Phoenix Chemicals Ltd | 0 | — |
| Solvias AG | 0 | — |
| Kanata Chemical Technologies | 0 | — |
Where to take this next
The landscape numbers point to where claim space is dense and where it is thin — the next step is turning that into a filing or freedom-to-operate decision specific to a given chemistry.
Check freedom-to-operate on a specific ligand class
With B01J and C07F claims covering roughly three-quarters of records, a specific ligand or metal system needs a targeted search against the leader's portfolio before committing R&D spend.
Explore in EurekaMap the fermentation and enzymatic white space
C12P records sit at just 2.4% of the 335 in scope, well below the catalytic routes — worth a closer look before assuming biocatalytic asymmetric synthesis is already crowded.
Run a deeper searchWatch for renewed filing activity
Every tracked leader shows zero filings in the latest year, but publication lag means 2025-2026 activity is still arriving. Re-check momentum in two quarters before concluding the field has gone quiet.
Set up monitoringCommon questions about this landscape
One assignee leads clearly with 93 of the 335 records in this scope, more than three times the fifth-place figure of 15. The top 5 assignees combined account for 47.5% of all records, and the top 10 account for 63.9%. Below that line, filing activity spreads across a long tail of smaller filers, so a freedom-to-operate check should prioritise the leader's portfolio first.
Filing rose from zero records in 2017 to a peak of 15 in 2020, then eased to 5 by the 2022 midpoint, and every tracked leading assignee shows zero filings in the latest year. That points to a field that has flattened rather than one still accelerating. Publication typically lags filing by around 18 months, so the most recent one to two years understate true activity and should not be read as a confirmed stop.
Fermentation and enzymatic synthesis (C12P) appears in only 2.4% of the 335 records, and addition-polymer-adjacent chemistry (C08F) sits at 2.7%, both well below the 75.5% carried by core catalysis claims under B01J. Medicinal-preparation crossover (A61K) is similarly thin at 3.6%. These lower-density branches are worth checking for open claim space before assuming the field is fully occupied.
US20220041595A1, assigned to Jazz Pharmaceuticals Ireland Limited and filed 2022-02-10, covers improved synthesis of fused bicyclic Raf inhibitor enantiomers at high enantiomeric excess, plus methods of using those compounds to treat cancers including colorectal cancer. It is relevant to anyone working on enantioselective synthesis routes to Raf inhibitor scaffolds, since it claims both the synthesis method and downstream therapeutic use. Teams working on structurally similar bicyclic inhibitors should review its claim scope directly before designing a synthesis route.
The United States receives the largest share at 91 filings, followed by Europe (EPO) at 47 and WIPO/PCT at 44. Australia (30), Canada (29) and Israel (21) each carry smaller but still meaningful shares. This spread suggests filers are pursuing a fairly standard multi-jurisdiction strategy rather than concentrating protection in one region, which matters when scoping where a competitor's coverage actually applies.
Research Asymmetric Catalysis and Chiral Synthesis in depth with Eureka
Go past this page: query the whole asymmetric catalysis and chiral synthesis corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.